期刊文献+

某院骨科2006~2010年鲍曼不动杆菌耐药及治疗情况分析 被引量:5

Drug resistance and therapy of Acinetobacter baumannii from 2006 to 2010 in an orthopaedic ward
下载PDF
导出
摘要 目的了解某院骨科2006~2010年鲍曼不动杆菌耐药及治疗情况,为临床合理使用抗菌药物提供依据。方法对某院骨科2006年1月~2010年12月鲍曼不动杆菌耐药及治疗情况进行回顾性分析。结果鲍曼不动杆菌的分离率自2006年逐年上升,2010年显著高于2006年。2010年,鲍曼不动杆菌除对米诺环素和头孢哌酮-舒巴坦耐药率较低外,对其他抗菌药物的耐药率均较高。临床治疗上存在抗菌药物滥用现象。结论鲍曼不动杆菌的分离率和耐药率逐年上升,应加强其耐药性监测,合理使用抗菌药物。 Objective To investigate the drug resistance and therapy of Acinetobacter baurnannii (Ab) from 2006 to 2010 in an orthopaedic ward. Methods A retrospective analysis was used for the drug resistance and therapy of Ab from 2006 to 2010. Results The isolation proportion of Ab strains was increasing year by year, which was significantly higher in 2010 than in 2006. The resistance rates of Ab were high to most antibiotics except ceioperazone-sulbactam and minocycline. There was antibiotic abuse in clinical practice. Conclusion The isolation proportion and resistant rate of Ab strains are increasing. We should monitor the drug resistance and use antibiotics more rationally.
出处 《中南药学》 CAS 2012年第2期154-157,共4页 Central South Pharmacy
关键词 鲍曼不动杆菌 骨科 耐药性 治疗 Ab orthopaedics drug resistance therapy
  • 相关文献

参考文献13

  • 1陈佰义,何礼贤,胡必杰,等.中国鲍曼不动杆菌感染诊治与防控专家共识(2011)[J].中华医学杂志.http://wenku.baidu.com/view/lelbb021192e45361066f545.html,http://infect.dxy.cn/article/2011/12/31/17221.
  • 2Zhou H, Yang O, Yu Ys, et al. Clonal Spread of Imipenem resistant Acinetobacter baumannii among different cities of China [J]. Clin Microbiol, 2007, 45 (12): 4054-4057.
  • 3史俊艳,张小江,徐英春,俞云松,杨青,汪复,朱德妹,倪语星,孙景勇,孙自镛,简翠,胡云健,艾效曼,张泓,李万华,贾蓓,黄文祥,王传清,薛建昌,魏莲花,吴玲,卓超,苏丹虹,张朝霞,季萍.2007年中国CHINET鲍曼不动杆菌耐药性监测[J].中国感染与化疗杂志,2009,9(3):196-200. 被引量:152
  • 4Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen [J]. Clin Microbiol Rev, 2008, 21(3): 538-582.
  • 5俞云松.多药耐药鲍曼不动杆菌——21世纪革兰阴性菌的“MRSA”[J].中华临床感染病杂志,2009,2(2):65-68. 被引量:93
  • 6Mahgoub S, Ahmed J, Glatt AE. Underlying characteristics of patients harboring highly resistant Acinetobacter baumannii [J]. Am J Infect Corntrol, 2002, 30 (7): 386-390.
  • 7邹明祥,梁伟,武文君,廖经忠,邬靖敏,刘文恩,范学工.长沙地区鲍曼不动杆菌临床分布特征及耐药性分析[J].中国现代医学杂志,2011,21(7):826-828. 被引量:13
  • 8Galani I, Flora K, Maria S, et al. Colistin susceptibility tes ting by Etest and disk diffusion methods [J]. Int J Antimicrob Agents, 2008, 31 (5): 434-439.
  • 9Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobaeter baumannii and Pseudomonas aeruginosa [J]. J Med Microbiol, 2006, 55 (12): 1619-1629.
  • 10Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram negative bacilli [J]. Clin Infect Dis, 2007, 45 (9): 1179-1181.

二级参考文献22

  • 1王辉,陈民钧,倪语星,陈冬梅,孙自庸,陈燕,赵旺胜,邹雄,俞云松,胡志东,黄心宏,徐英春,谢秀丽,褚云卓,王倩,梅亚宁,田彬,张蓓,孔庆莲,于秀娟,潘玉红.2003—2004年中国十家教学医院革兰阴性杆菌的耐药分析[J].中华检验医学杂志,2005,28(12):1295-1303. 被引量:236
  • 2石岩,刘大为,许大波,徐英春,陈民均,王辉.泛耐药鲍曼不动杆菌感染临床治疗初探[J].中国感染与化疗杂志,2007,7(1):34-37. 被引量:112
  • 3汪复.多重耐药铜绿假单胞菌与鲍曼不动杆菌严重感染的防治策略[J].中国感染与化疗杂志,2007,7(3):230-232. 被引量:138
  • 4Clinical and Laboratory Standards Institute 2008. Performance standards for antimierobial susceptibility testing: eighteenth informational supplement M100-S18[S]. CLSI, 2008.
  • 5Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species[J]. Clin Infect Dis, 2006,43(Suppl 2):S43-S48.
  • 6Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections[J ]. Lancet Infect Dis, 2008,8 (12) : 751-762.
  • 7Gales AC,Jones RN,Sader HS. Global assessment of the antimicrobial activity of polymycin B against 54 731 clinical isolates of Gram-negtive bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004) [J]. Clin Microbiol Infect, 2006,12(4):315- 321.
  • 8Rafailidis PI, Ioannidou EN, Falagas ME. Ampicillin/sulbactam: current status in severe bacterial infections[J]. Drugs, 2007,67(13) : 1829-1849.
  • 9Henwood CJ, Gatward T, Warner M, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)[J ]. J Antimicrob Chemother, 2002,49(3):479-487.
  • 10Timurkaynak F,Can F,Azap OK,et al. In vitro activities of non-traditional antimicrobials alone or in combination agaist multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units [J]. Int J Antimicrob Agents, 2006,27(3):224-228.

共引文献250

同被引文献56

  • 1张昭勇,李晓强.碳青霉烯耐药与非耐药鲍曼不动杆菌多重耐药性分析[J].现代中两医结合杂志,2012,2l(7):761-763.
  • 2李小宁,李娟,姚永红.鲍曼不动杆菌的耐药性及产ESBL和碳青霉烯酶分析[J].中国l临床药理学与治疗学,2012,17(1):30-33.
  • 3Harms JM,Bartels H,Schlunzen F,et al.Antibiotics acting on the translational machinery[J].J Cell Sci,2003,116(8):1 391.
  • 4Hirata T,Nomura W,Imanishi M,et al.Effects of linking 15-zinc finger domains on DNA binding specificity and multiple DNA binding modes[J].Bioorg Med Chem Lett,2005,15(9):2 197.
  • 5FDA.Tygacil(tigecycline)for injection[EB/OL].(2013-09-30)[2015-04-05].http://www.fda.gov/Safety/MedW-atch/Safety Information/ucm228387.htm.
  • 6Bradford PA,Weaver-Sands DT,Petersen PJ.In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections[J].Clin Infect Dis,2005,41(5):S315.
  • 7Sader HS,Farrell DJ,Flamm RK,et al.Variation in potency and spectrum of tigecycline activity against bacterial strains from US medical centers since its approval for clinical use:2006-2012[J].Antimicrob Agents Ch,2014,58(4):2 274.
  • 8Gupta S,Aruna C,Nagaraj S,et al.In vitro activity of tigecycline against multidrug-resistant gram-negative blood culture isolates from critically ill patients[J].J Antimicrob Chemother,2012,67(5):1 293.
  • 9Babinchak T,Ellis-Grosse E,Dartois N,et al.The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections:analysis of pooled clinical trial data[J].Clin Infect Dis,2005,41(5):S354.
  • 10Ellis-Grosse EJ,Babinchak T,Dartois N,et al.The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections:results of 2 double-blind phase 3comparison studies with vancomycin-aztreonam[J].Clin Infect Dis,2005,41(5):S341.

引证文献5

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部